Molecular and traditional chemotherapy: A united front against prostate cancer

Cancer Letters

Volumn 293, Issue 1, 2010, Pages 1-14

  Singh, P ^c   Yam, M ^a,b   Russell, P J ^a,b,d,e   Khatri, A ^a,b  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c GRIFFITH UNIVERSITY   (Australia)

^d Translational Research Institute   (Australia)

^e QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Chemotherapy; Conditionally replicating adenovirus; Docetaxel; Gene directed pro drug enzyme therapy; Molecular chemotherapy; Purine nucleoside phosphorylase

Indexed keywords

2 METHOXYESTRADIOL; ACICLOVIR; ADENOVIRUS VECTOR; ANGIOGENESIS INHIBITOR; ANTISENSE OLIGODEOXYNUCLEOTIDE; CALCITRIOL; CANCER VACCINE; CARBOPLATIN; CELECOXIB; CYTOSINE DEAMINASE; DOCETAXEL; ENOXAPARIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ESTRAMUSTINE; FLUDARABINE PHOSPHATE; FLUOROURACIL; GANCICLOVIR; HYDROCORTISONE; MITOXANTRONE; NAVELBINE; PACLITAXEL; PREDNISONE; PURINE NUCLEOSIDE PHOSPHORYLASE; SULINDAC SULFONE; THALIDOMIDE; THYMIDINE KINASE; UNINDEXED DRUG; VALACICLOVIR; WARFARIN; ZOLEDRONIC ACID;

ADVANCED CANCER; ALOPECIA; APOPTOSIS; BYSTANDER EFFECT; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CASTRATION; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DYSPNEA; FATIGUE; GENE DIRECTED ENZYME PRODRUG THERAPY; HUMAN; METABOLIC DISORDER; MOLECULAR THERAPY; MONOTHERAPY; NAIL DISEASE; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUTROPENIA; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; SHORT SURVEY; TRANSGENE; UNSPECIFIED SIDE EFFECT;

ADENOVIRIDAE;

EID: 77952427224     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.11.019     Document Type: Review

References (167)

1. Wu J.T., Wu T.L., Chang C.P.Y., Tang K.C., F Sun C. Different patterns of serum chromogranin A in patients with prostate cancer with and without undergoing hormonal therapy. J. Clin. Lab. Anal. 1999, 13:308-311.
2. Russell P.J., Khatri A. Novel gene-directed enzyme prodrug therapies against prostate cancer. Expert Opin. Investig. Drugs 2006, 15:947-961.
3. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., Oudard S., Theodore C., James N.D., Turesson I., Rosenthal M.A., Eisenberger M.A. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl. J. Med. 2004, 351:1502-1512.
4. Petrylak D.P., Tangen C.M., Hussain M.H., Lara P.N., Jones J.A., Taplin M.E., Burch P.A., Berry D., Moinpour C., Kohli M., Benson M.C., Small E.J., Raghavan D., Crawford E.D. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New Engl. J. Med. 2004, 351:1513-1520.
5. Moon C., Park J.C., Chae Y.K., Yun J.H., Kim S. Current status of experimental therapeutics for prostate cancer. Cancer Lett. 2008, 266:116-134.
6. So A., Gleave M., Hurtado-Col A., Nelson C. Mechanisms of the development of androgen independence in prostate cancer. World J. Urol. 2005, 23:1-9.
7. Prostate Cancer Foundation of Australia, Post diagnosis, New South Wales: Prostate Cancer Foundation of Australia, 2009. <>http://www.prostate.org.au/articleLive/pages/Post-diagnosis.html.
8. Simmons M., Klein E. Combined androgen blockade revisited: emerging options for the treatment of castration-resistant prostate cancer. Urology 2009, 73:697-705.
9. Berthold D.R., Sternberg C.N., Tannock I.F. Management of advanced prostate cancer after first-line chemotherapy. J. Clin. Oncol. 2005, 23:8247-8252.
10. Wolff J.M. Chemotherapy in hormone-refractory prostate cancer. Front. Radiat. Ther. Oncol. 2008, 41:103-107.
11. Petrylak D.P. The current role of chemotherapy in metastatic hormone-refractory prostate cancer. Urology 2005, 65:3-7. (discussion 7-8).
12. Chowdhury S., Burbridge S., Harper P.G. Chemotherapy for the treatment of hormone-refractory prostate cancer. Int. J. Clin. Pract. 2007, 61:2064-20670.
13. Tannock I.F., Osoba D., Stockler M.R., Ernst D.S., Neville A.J., Moore M.J., Armitage G.R., Wilson J.J., Venner P.M., Coppin C.M., Murphy K.C. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. 1996, 14:1756-1764.
14. Picus J., Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin. Oncol. 1999, 26:14-18.
15. Berry W., Dakhil S., Gregurich M.A., Asmar L. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin. Oncol. 2001, 28:8-15.
16. Beer T.M., Berry W., Wersinger E.M., Bland L.B. Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70. Clin. Prostate Cancer 2003, 2:167-172.
17. Khan M.A., Carducci M.A., Partin A.W. Docetaxel in androgen-independent prostate cancer: an update. BJU Int. 2004, 94:1209-1216.
18. Sissung T.M., Danesi R., Price D.K., Steinberg S.M., de Wit R., Zahid M., Gaikwad N., Cavalieri E., Dahut W.L., Sackett D.L., Figg W.D., Sparreboom A. Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Mol. Cancer Ther. 2008, 7:19-26.
19. Figg W.D., Li H., Sissung T., Retter A., Wu S., Gulley J.L., Arlen P., Wright J.J., Parnes H., Fedenko K., Latham L., Steinberg S.M., Jones E., Chen C., Dahut W. Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. BJU Int. 2007, 99:1047-1055.
20. Di Lorenzo G., Figg W.D., Fossa S.D., Mirone V., Autorino R., Longo N., Imbimbo C., Perdona S., Giordano A., Giuliano M., Labianca R., De Placido S. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur. Urol. 2008, 54:1089-1094.
21. Gross M., Higano C., Pantuck A., Castellanos O., Green E., Nguyen K., Agus D.B. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer 2007, 7:142.
22. Arlen P.M., Gulley J.L., Parker C., Skarupa L., Pazdur M., Panicali D., Beetham P., Tsang K.Y., Grosenbach D.W., Feldman J., Steinberg S.M., Jones E., Chen C., Marte J., Schlom J., Dahut W. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin. Cancer Res. 2006, 12:1260-1269.
23. Gleave M.E., Miayake H., Goldie J., Nelson C., Tolcher A. Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides. Urology 1999, 54:36-46.
24. Sleijfer S., Stoter G. Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer?. Nat. Clin. Pract. Urol. 2005, 2:18-19.
25. Caffo O., Sava T., Comploj E., Giampaolo M.A., Segati R., Valduga F., Cetto G., Galligioni E. Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone. Urol. Oncol. 2008.
26. Savarese D.M., Halabi S., Hars V., Akerley W.L., Taplin M.E., Godley P.A., Hussain A., Small E.J., Vogelzang N.J. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J. Clin. Oncol. 2001, 19:2509-2516.
27. Savarese D., Taplin M.E., Halabi S., Hars V., Kreis W., Vogelzang N. A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormonerefractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780. Semin. Oncol. 1999, 26:39-44.
28. Boehmer A., Anastasiadis A.G., Feyerabend S., Nagele U., Kuczyk M., Schilling D., Corvin S., Merseburger A.S., Stenzl A. Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience. Anticancer Res. 2005, 25:4481-4486.
29. Oudard S., Banu E., Beuzeboc P., Voog E., Dourthe L.M., Hardy-Bessard A.C., Linassier C., Scotte F., Banu A., Coscas Y., Guinet F., Poupon M.F., Andrieu J.M. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormonerefractory prostate cancer. J. Clin. Oncol. 2005, 23:3343-3351.
30. Kikuno N., Urakami S., Nakamura S., Hiraoka T., Hyuga T., Arichi N., Wake K., Sumura M., Yoneda T., Kishi H., Shigeno K., Shiina H., Igawa M. Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer. Eur. Urol. 2007, 51:1252-1258.
31. Oh W.K., Halabi S., Kelly W.K., Werner C., Godley P.A., Vogelzang N.J., Small E.J. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colonystimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer 2003, 98:2592-2598.
32. Tiffany N.M., Ryan C.W., Garzotto M., Wersinger E.M., Beer T.M. High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study. J. Urol. 2005, 174:888-892.
33. Hahn N.M., Marsh S., Fisher W., Langdon R., Zon R., Browning M., Johnson C.S., Scott-Horton T.J., Li L., McLeod H.L., Sweeney C.J. Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormonerefractory prostate cancer with pharmacogenetic survival analysis. Clin. Cancer Res. 2006, 12:6094-6099.
34. Carles J., Font A., Mellado B., Domenech M., Gallardo E., Gonzalez-Larriba J.L., Catalan G., Alfaro J., Gonzalez Del Alba A., Nogue M., Lianes P., Tello J.M. Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study. Brit. J. Cancer 2007, 97:1206-1210.
35. Dawson N.A., Halabi S., Ou S.S., Biggs D.D., Kessinger A., Vogelzang N., Clamon G.H., Nanus D.M., Kelly W.K., Small E.J. A phase II study of estramustine, docetaxel, and exisulind in patients with hormone-refractory prostate cancer: results of cancer and leukemia group B trial 90004. Clin. Genitourin Cancer 2008, 6:110-116.
36. Gonzalez-Martin A., Fernandez E., Vaz M.A., Burgos J., Lopez Garcia M., Rodriguez Patron R., Guillen C., Mayayo T., Allona A., Arias F., Moyano A. Long-term outcome of a phase II study of weekly docetaxel with a short course of estramustine and enoxaparine in hormone-resistant prostate cancer patients. Clin. Transl. Oncol. 2007, 9:323-328.
37. Kattan J.G., Farhat F.S., Chahine G.Y., Nasr F.L., Moukadem W.T., Younes F.C., Yazbeck N.J., Ghosn M.G. Weekly docetaxel, zoledronic acid and estramustine in hormonerefractory prostate cancer (HRPC). Invest. New Drugs 2008, 26:75-79.
38. Moser L., Schostak M., Miller K., Hinkelbein W. Controversies in the treatment of prostate cancer. Front. Radiat. Ther. Oncol. 2008, 41:103-107.
39. Benelli R., Monteghirfo S., Balbi C., Barboro P., Ferrari N. Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a player. Int. J. Cancer 2009, 124:2989-2996.
40. Reiner T., de las Pozas A., Gomez L.A., Perez-Stable C. Low dose combinations of 2-methoxyestradiol and docetaxel block prostate cancer cells in mitosis and increase apoptosis. Cancer Lett. 2009, 276:21-31.
41. Wilson C., Scullin P., Worthington J., Seaton A., Maxwell P., O'Rourke D., Johnston P.G., McKeown S.R. Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer. Brit. J. Cancer 2008, 99:2054-2064.
42. Friedland D., Cohen J., Miller R., Voloshin M., Gluckman R., Lembersky B., Zidar B., Keating M., Reilly N., Dimitt B. A phase II trial of docetaxel (Taxotere) in hormonerefractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin. Oncol. 1999, 26:19-23.
43. Beer T.M., Pierce W.C., Lowe B.A., Henner W.D. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann. Oncol. 2001, 12:1273-1279.
44. Gravis G., Bladou F., Salem N., Macquart-Moulin G., Serment G., Camerlo J., Genre D., Bardou V.J., Maraninchi D., Viens P. Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma. Cancer 2003, 98:1627-1634.
45. Petrylak D.P. Docetaxel (Taxotere) in hormone-refractory prostate cancer. Semin. Oncol. 2000, 27:24-29.
46. Sinibaldi V.J., Carducci M.A., Moore-Cooper S., Laufer M., Zahurak M., Eisenberger M.A. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer 2002, 94:1457-1465.
47. Mancuso A., Oudard S., Sternberg C.N. Effective chemotherapy for hormone-refractory prostate cancer (HRPC): present status and perspectives with taxane-based treatments. Crit. Rev. Oncol. Hematol. 2007, 61:176-185.
48. Bridgewater J.A., Knox R.J., Pitts J.D., Collins M.K., Springer C.J. The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite. Hum. Gene Ther. 1997, 8:709-717.
49. Kunishige I., Samejima Y., Moriyama A., Saji F., Murata Y. cAMP stimulates the bystander effect in suicide gene therapy of human choriocarcinoma. Anticancer Res. 1998, 18:3411-3419.
50. Freeman S.M., Zwiebel J.A. Gene therapy of cancer. Cancer Invest. 1993, 11:676-688.
51. Ram Z., Walbridge S., Shawker T., Culver K.W., Blaese R.M., Oldfield E.H. The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J. Neurosurg. 1994, 81:256-260.
52. Freeman S.M., Ramesh R., Shastri M., Munshi A., Jensen A.K., Marrogi A.J. The role of cytokines in mediating the bystander effect using HSV-tk xenogeneic cells. Cancer Lett. 1995, 92:167-174.
53. Gagandeep S., Brew R., Green B., Christmas S.E., Klatzmann D., Poston G.J., Kinsella A.R. Prodrug-activated gene therapy: involvement of an immunological component in the " bystander effect" Cancer Gene Ther. 1996, 3:83-88.
54. Niculescu-Duvaz I., Springer C.J. Introduction to the background, principles, and state of the art in suicide gene therapy. Mol. Biotechnol. 2005, 30:71-88.
55. Silva A.T., Chung M.C., Castro L.F., Guido R.V., Ferreira E.I. Advances in prodrug design. Mini Rev. Med. Chem. 2005, 5:893-914.
56. Culver K.W., Osborne W.R., Miller A.D., Fleisher T.A., Berger M., Anderson W.F., Blaese R.M. Correction of ADA deficiency in human T lymphocytes using retroviral-mediated gene transfer. Transplant. Proc. 1991, 23:170-171.
57. John Wiley and Sons Ltd., Vectors Used in Gene Therapy Clinical Trials, Wiley (2009), Retrieved sept.2009 from http://www.wiley.co.uk/genetherapy/clinical/.
58. Freytag S.O., Stricker H., Movsas B., Kim J.H. Prostate cancer gene therapy clinical trials. Mol. Ther. 2007, 15:1042-1052.
59. Kubo H., Gardner T.A., Wada Y., Koeneman K.S., Gotoh A., Yang L., Kao C., Lim S.D., Amin M.B., Yang H., Black M.E., Matsubara S., Nakagawa M., Gillenwater J.Y., Zhau H.E., Chung L.W. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum. Gene Ther. 2003, 14:227-241.
60. Portsmouth D., Hlavaty J., Renner M. Suicide genes for cancer therapy. Mol. Aspects Med. 2007, 28:4-41.
61. Hasenburg A., Tong X.W., Rojas-Martinez A., Nyberg-Hoffman C., Kieback C.C., Kaplan A.L., Kaufman R.H., Ramzy I., Aguilar-Cordova E., Kieback D.G. Thymidine kinase (TK) gene therapy of solid tumors: valacyclovir facilitates outpatient treatment. Anticancer Res. 1999, 19:2163-2165.
62. Cheon J., Kim H.K., Moon D.G., Yoon D.K., Cho J.H., Koh S.K. Adenovirus-mediated suicide-gene therapy using the herpes simplex virus thymidine kinase gene in cell and animal models of human prostate cancer: changes in tumour cell proliferative activity. BJU Int. 2000, 85:759-766.
63. Eastham J.A., Chen S.H., Sehgal I., Yang G., Timme T.L., Hall S.J., Woo S.L., Thompson T.C. Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum. Gene Ther. 1996, 7:515-523.
64. Ayala G., Satoh T., Li R., Shalev M., Gdor Y., Aguilar-Cordova E., Frolov A., Wheeler T.M., Miles B.J., Rauen K., Teh B.S., Butler E.B., Thompson T.C., Kadmon D. Biological response determinants in HSV-tk+ganciclovir gene therapy for prostate cancer. Mol. Ther. 2006, 13:716-728.
65. Brown N.L., Lemoine N.R. Clinical trials with GDEPT: cytosine deaminase and 5-fluorocytosine. Meth. Mol. Med. 2004, 90:451-457.
66. Khatri A., Zhang B., Doherty E., Chapman J., Ow K., Pwint H., Martiniello-Wilks R., Russell P.J. Combination of cytosine deaminase with uracil phosphoribosyl transferase leads to local and distant bystander effects against RM1 prostate cancer in mice. J. Gene Med. 2006, 8:1086-1096.
67. P.J. Russell, A. Khatri, B. Zhang, E. Doherty, K. Ow, J. Chapman, R. Martiniello-Wilks, Gene directed enzyme prodrug therapy using the fusion gene, cytosine deaminase uracil phosphoribosyl transferase leads to a distant bystander effect in mouse models of prostate cancer, Proc Amer Assoc Cancer Res. 46 (2005).
68. Miyagi T., Koshida K., Hori O., Konaka H., Katoh H., Kitagawa Y., Mizokami A., Egawa M., Ogawa S., Hamada H., Namiki M. Gene therapy for prostate cancer using the cytosine deaminase/uracil phosphoribosyltransferase suicide system. J. Gene Med. 2003, 5:30-37.
69. Xie Y., Gilbert J.D., Kim J.H., Freytag S.O. Efficacy of adenovirus-mediated CD/5-FC and HSV-1 thymidine kinase/ganciclovir suicide gene therapies concomitant with p53 gene therapy. Clin. Cancer Res. 1999, 5:4224-4232.
70. Freytag S.O., Khil M., Stricker H., Peabody J., Menon M., DePeralta-Venturina M., Nafziger D., Pegg J., Paielli D., Brown S., Barton K., Lu M., Aguilar-Cordova E., Kim J.H. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 2002, 62:4968-4976.
71. Lipinski K.S., Pelech S., Mountain A., Irvine A.S., Kraaij R., Bangma C.H., Mills K.H., Todryk S.M. Nitroreductase-based therapy of prostate cancer, enhanced by raising expression of heat shock protein 70, acts through increased anti-tumour immunity. Cancer Immunol. Immunother. 2006, 55:347-354.
72. Djeha A.H., Thomson T.A., Leung H., Searle P.F., Young L.S., Kerr D.J., Harris P.A., Mountain A., Wrighton C.J. Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors. Mol. Ther. 2001, 3:233-240.
73. Zhou D., Lu Y., Steiner M.S., Dalton J.T. Cytochrome P-450 2C9 sensitizes human prostate tumor cells to cyclophosphamide via a bystander effect. Antimicrob. Agents Chemother. 2000, 44:2659-2663.
74. Jounaidi Y., Waxman D.J. Use of replication-conditional adenovirus as a helper system to enhance delivery of P450 prodrug-activation genes for cancer therapy. Cancer Res. 2004, 64:292-303.
75. Mesnil M., Yamasaki H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res. 2000, 60:3989-3999.
76. Ebara S., Shimura S., Nasu Y., Kaku H., Kumon H., Yang G., Wang J., Timme T.L., Aguilar-Cordova E., Thompson T.C. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters. Prostate Cancer Prostatic Dis. 2002, 5:316-325.
77. Hall S.J., Sanford M.A., Atkinson G., Chen S.H. Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer. Cancer Res. 1998, 58:3221-3225.
78. Dachs G.U., Tupper J., Tozer G.M. From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs 2005, 16:349-359.
79. Hall S.J., Mutchnik S.E., Yang G., Timme T.L., Nasu Y., Bangma C.H., Woo S.L., Shaker M., Thompson T.C. Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer. Cancer Gene Ther. 1999, 6:54-63.
80. Freytag S.O., Stricker H., Pegg J., Paielli D., Pradhan D.G., Peabody J., DePeralta-Venturina M., Xia X., Brown S., Lu M., Kim J.H. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate - to high-risk prostate cancer. Cancer Res. 2003, 63:7497-7506.
81. Chhikara M., Huang H., Vlachaki M.T., Zhu X., Teh B., Chiu K.J., Woo S., Berner B., Smith E.O., Oberg K.C., Aguilar L.K., Thompson T.C., Butler E.B., Aguilar-Cordova E. Enhanced therapeutic effect of HSV-tk+GCV gene therapy and ionizing radiation for prostate cancer. Mol. Ther. 2001, 3:536-542.
82. Atkinson G., Hall S.J. Prodrug activation gene therapy and external beam irradiation in the treatment of prostate cancer. Urology 1999, 54:1098-1104.
83. Varghese S., Rabkin S.D., Liu R., Nielsen P.G., Ipe T., Martuza R.L. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Ther. 2006, 13:253-265.
84. Hall S.J., Canfield S.E., Yan Y., Hassen W., Selleck W.A., Chen S.H. A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer. Gene Ther. 2002, 9:511-517.
85. Nasu Y., Bangma C.H., Hull G.W., Yang G., Wang J., Shimura S., McCurdy M.A., Ebara S., Lee H.M., Timme T.L., Thompson T.C. Combination gene therapy with adenoviral vector-mediated HSV-tk+GCV and IL-12 in an orthotopic mouse model for prostate cancer. Prostate Cancer Prostatic Dis. 2001, 4:44-55.
86. Fukuhara H., Martuza R.L., Rabkin S.D., Ito Y., Todo T. Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma. Clin. Cancer Res. 2005, 11:7886-7890.
87. Varghese S., Rabkin S.D. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther. 2002, 9:967-978.
88. Varghese S., Newsome J.T., Rabkin S.D., McGeagh K., Mahoney D., Nielsen P., Todo T., Martuza R.L. Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates. Hum. Gene Ther. 2001, 12:999-1010.
89. Jorgensen T.J., Katz S., Wittmack E.K., Varghese S., Todo T., Rabkin S.D., Martuza R.L. Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer. Neoplasia 2001, 3:451-456.
90. Freytag S.O., Stricker H., Pegg J., Paielli D., Pradhan D.G., Peabody J., DePeralta-Venturina M., Xia X., Brown S., Lu M., Kim J.H. Phase I study of replication competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate - to high-risk PC 2003, 63.
91. Zhang P., Zeng H., Wei Q., Lu Y., Li X., Wang J., Zhao F., Li H. Improved effects of a double suicide gene system on prostate cancer cells by targeted regulation of prostatespecific membrane antigen promoter and enhancer. Int. J. Urol. 2008, 15:442-448.
92. Khatri A., Husaini Y., Ow K., Chapman J., Russell P.J. cytosine DEAMINASE-uracil phosphoribosyltransferase and Interleukin (IL)-12 and IL-18: a multimodal anticancer interface marked by specific modulation in serum cytokines. Clin. Cancer Res. 2009, 15:2323-2334.
93. Bzowskaa A., Kulikowskaa E., Shugar D., properties Purine nucleoside phosphorylases: functions and clinical aspects. Pharmacology and Therapeutics 2000, 88:349-425.
94. Zhang Y., Parker W.B., Sorscher E.J., Ealick S.E. PNP anticancer gene therapy. Curr. Top. Med. Chem. 2005, 5:1259-1274.
95. Parker W.B., Allan P.W., Shaddix S.C., Rose L.M., Speegle H.F., Gillespie G.Y., Bennett L.L. Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells. Biochem. Pharmacol. 1998, 55:1673-1681.
96. Lockett L.J., Molloy P.L., Russell P.J., Both G.W. Relative efficiency of tumor cell killing in vitro by two enzyme-prodrug systems delivered by identical adenovirus vectors. Clin. Cancer Res. 1997, 3:2075-2080.
97. Sorscher E.J., Peng S., Bebok Z., Allan P.W., Bennett L.L., Parker W.B. Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines. Gene Ther 1994, 1:233-238.
98. Patel P., Ashdown D., James N. Is gene therapy the answer for prostate cancer?. Prostate Cancer Prostatic. Dis. 2004, 7(Suppl 1):S14-19.
99. Carroll A.G., Voeller H.J., Sugars L., Gelmann E.P. p53 oncogene mutations in three human prostate cancer cell lines. Prostate 1993, 23:123-134.
100. Wang X.Y., Martiniello-Wilks R., Shaw J.M., Ho T., Coulston N., Cooke-Yarborough C., Molloy P.L., Cameron F., Moghaddam M., Lockett T.J., Webster L.K., Smith I.K., Both G.W., Russell P.J. Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus. Gene Ther. 2004, 11:1559-1567.
101. Krohne T.U., Shankara S., Geissler M., Roberts B.L., Wands J.R., Blum H.E., Mohr L. Mechanisms of cell death induced by suicide genes encoding purine nucleoside phosphorylase and thymidine kinase in human hepatocellular carcinoma cells in vitro. Hepatology 2001, 34:511-518.
102. Martiniello-Wilks R., Dane A., Voeks D.J., Jeyakumar G., Mortensen E., Shaw J.M., Wang X.Y., Both G.W., Russell P.J. Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease. J. Gene Med. 2004, 6:43-54.
103. NCT00625430: A Phase I Gene Therapy Study of FP253/Fludarabine for Prostate Cancer FP253-, in, Biotech Equity Partners Pty Ltd. (Feb. 2008) http://clinicaltrials.gov./ct2/show/NCT00625430.
104. Martiniello-Wilks R., Garcia-Aragon J., Daja M.M., Russell P., Both G.W., Molloy P.L., Lockett L.J., Russell P.J. In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors. Hum. Gene Ther. 1998, 9:1617-1626.
105. Voeks D., Martiniello-Wilks R., Madden V., Smith K., Bennetts E., Both G.W., Russell P.J. Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models. Gene Ther. 2002, 9:759-768.
106. Martiniello-Wilks R., Wang X.Y., Voeks D.J., Dane A., Shaw J.M., Mortensen E., Both G.W., Russell P.J. Purine nucleoside phosphorylase and fludarabine phosphate gene directed enzyme prodrug therapy suppresses primary tumour growth and pseudometastases in a mouse model of prostate cancer. J. Gene Med. 2004, 6:1343-1357.
107. Green N.K., Seymour L.W. Adenoviral vectors: systemic delivery and tumor targeting. Cancer Gene Ther. 2002, 9:1036-1042.
108. Morille M., Passirani C., Vonarbourg A., Clavreul A., Benoit J.P. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials 2008, 29:3477-3496.
109. Majhen D., Ambriovic-Ristov A. Adenoviral vectors - how to use them in cancer gene therapy?. Virus Res. 2006, 119:121-133.
110. Amalfitano A., Hauser M.A., Hu H., Serra D., Begy C.R., Chamberlain J.S. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J. Virol. 1998, 72:926-933.
111. Lusky M., Christ M., Rittner K., Dieterle A., Dreyer D., Mourot B., Schultz H., Stoeckel F., Pavirani A., Mehtali M. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J. Virol. 1998, 72:2022-2032.
112. Lusky M., Grave L., Dieterle A., Dreyer D., Christ M., Ziller C., Furstenberger P., Kintz J., Hadji D.A., Pavirani A., Mehtali M. Regulation of adenovirus-mediated transgene expression by the viral E4 gene products: requirement for E4 ORF3. J. Virol. 1999, 73:8308-8319.
113. Moorhead J.W., Clayton G.H., Smith R.L., Schaack J. A replication-incompetent adenovirus vector with the preterminal protein gene deleted efficiently transduces mouse ears. J. Virol. 1999, 73:1046-1053.
114. Engelhardt J.F., Ye X., Doranz B., Wilson J.M. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. USA 1994, 91:6196-6200.
115. Lieber A., Steinwaerder D.S., Carlson C.A., Kay M.A. Integrating adenovirus-adeno associated virus hybrid vectors devoid of all viral genes. J. Virol. 1999, 73:9314-9324.
116. Steinwaerder D.S., Carlson C.A., Lieber A. Generation of adenovirus vectors devoid of all viral genes by recombination between inverted repeats. J. Virol. 1999, 73:9303-9313.
117. Kelly E., Russell S.J., Kelly E., Russell S.J. History of oncolytic viruses: genesis to genetic engineering. Mol. Ther. 2007, 15:651-659.
118. Heise C., Ganly I., Kim Y.T., Sampson-Johannes A., Brown R., Kirn D. Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status. Gene Ther. 2000, 7:1925-1929.
119. Nemunaitis J., Cunningham C., Buchanan A., Blackburn A., Edelman G., Maples P., Netto G., Tong A., Randlev B., Olson S., Kirn D. Intravenous infusion of a replication selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther. 2001, 8:746-759.
120. Kraaij R., van Rijswijk A.L., Oomen M.H., Haisma H.J., Bangma C.H., van Rijswijk A.L.C.T., Oomen M.H.A. Prostate specific membrane antigen (PSMA) is a tissue specific target for adenoviral transduction of prostate cancer in vitro. Prostate 2005, 62:253-259.
121. Bangma C.H., Kraaij R., van Rijswijk A., Haisma H.J., van Beusechem V., Gerritsen W. Transductional targeting of adenoviral vectors to prostate cancer in vitro. Prostate Cancer Prostat. Dis. 1999, 2:S5.
122. Rajecki M., Kanerva A., Stenman U.-H., Tenhunen M., Kangasniemi L., Sarkioja M., Ala-Opas M.Y., Alfthan H., Sankila A., Rintala E., Desmond R.A., Hakkarainen T., Hemminki A. Treatment of prostate cancer with Ad5/3Delta24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo. Mol. Cancer Ther. 2007, 6:742-751.
123. Suzuki K., Fueyo J., Krasnykh V., Reynolds P.N., Curiel D.T., Alemany R. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin. Cancer Res. 2001, 7:120-126.
124. Shirakawa T., Terao S., Hinata N., Tanaka K., Takenaka A., Hara I., Sugimura K., Matsuo M., Hamada K., Fuji K., Okegawa T., Higashihara E., Gardner T.A., Kao C., Chung L.W., Kamidono S., Fujisawa M., Gotoh A. Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer. Hum. Gene Ther. 2007, 18:1225-1232.
125. Koeneman K.S., Kao C., Ko S.C., Yang L., Wada Y., Kallmes D.F., Gillenwater J.Y., Zhau H.E., Chung L.W., Gardner T.A. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World J. Urol. 2000, 18:102-110.
126. Hsieh C.L., Gardner T.A., Miao L., Balian G., Chung L.W. Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells. Cancer Gene Ther. 2004, 11:148-155.
127. Matsubara S., Wada Y., Gardner T.A., Egawa M., Park M.S., Hsieh C.L., Zhau H.E., Kao C., Kamidono S., Gillenwater J.Y., Chung L.W. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res. 2001, 61:6012-6019.
128. McCarthy H.O., Coulter J.A., Worthington J., Robson T., Hirst D.G. Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory prostate cancer. J. Gene Med. 2007, 9:511-520.
129. Pariente N., Morizono K., Virk M.S., Petrigliano F.A., Reiter R.E., Lieberman J.R., Chen I.S. A novel dual-targeted lentiviral vector leads to specific transduction of prostate cancer bone metastases in vivo after systemic administration. Mol. Ther. 2007, 15:1973-1981.
130. Adams J.Y., Johnson M., Sato M., Berger F., Gambhir S.S., Carey M., Iruela-Arispe M.L., Wu L. Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging. Nat. Med. 2002, 8:891-897.
131. Zeng H., Wei Q., Huang R., Chen N., Dong Q., Yang Y., Zhou Q. Recombinant adenovirus mediated prostate-specific enzyme pro-drug gene therapy regulated by prostate-specific membrane antigen (PSMA) enhancer/promoter. J. Androl. 2007, 28:827-835.
132. Lee S.J., Kim H.S., Yu R., Lee K., Gardner T.A., Jung C., Jeng M.H., Yeung F., Cheng L., Kao C. Novel prostate-specific promoter derived from PSA and PSMA enhancers. Mol. Ther. 2002, 6:415-421.
133. Lee S.J., Zhang Y., Lee S.D., Jung C., Li X., Kim H.S., Bae K.H., Jeng M.H., Kao C., Gardner T. Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer. Mol. Ther. 2004, 10:1051-1058.
134. Ahn M., Lee S.J., Li X., Jimenez J.A., Zhang Y.P., Bae K.H., Mohammadi Y., Kao C., Gardner T.A. Enhanced combined tumor-specific oncolysis and suicide gene therapy for prostate cancer using M6 promoter. Cancer Gene Ther. 2009, 16:73-82.
135. Kraaij R., van der Weel L., de Ridder C.M., van der Korput H.A., Zweistra J.L., van Rijswijk A.L., Bangma C.H., Trapman J. A small chimeric promoter for high prostate-specific transgene expression from adenoviral vectors. Prostate 2007, 67:829-839.
136. Zhang Y., Yu J., Unni E., Shao T.C., Nan B., Snabboon T., Kasper S., Andriani F., Denner L., Marcelli M. Monogene and polygene therapy for the treatment of experimental prostate cancers by use of apoptotic genes bax and bad driven by the prostate-specific promoter ARR(2)PB. Hum. Gene Ther. 2002, 13:2051-2064.
137. Yu D., Scott C., Jia W.W., De Benedetti A., Williams B.J., Fazli L., Wen Y., Gleave M., Nelson C., Rennie P.S. Targeting and killing of prostate cancer cells using lentiviral constructs containing a sequence recognized by translation factor eIF4E and a prostatespecific promoter. Cancer Gene Ther. 2006, 13:32-43.
138. Yu D., Chen D., Chiu C., Razmazma B., Chow Y.H., Pang S. Prostate-specific targeting using PSA promoter-based lentiviral vectors. Cancer Gene Ther. 2001, 8:628-635.
139. Park H.S., Cheon J., Cho H.Y., Ko Y.H., Bae J.H., Moon D.G., Kim J.J. In vivo characterization of a prostate-specific antigen promoter-based suicide gene therapy for the treatment of benign prostatic hyperplasia. Gene Ther. 2003, 10:1129-1134.
140. Martiniello-Wilks R., Tsatralis T., Russell P., Brookes D.E., Zandvliet D., Lockett L.J., Both G.W., Molloy P.L., Russell P.J. Transcription-targeted gene therapy for androgenin dependent prostate cancer. Cancer Gene Ther. 2002, 9:443-452.
141. Sarkar D., Lebedeva I.V., Su Z.Z., Park E.S., Chatman L., Vozhilla N., Dent P., Curiel D.T., Fisher P.B. Eradication of therapy-resistant human prostate tumors using a cancer terminator virus. Cancer Res. 2007, 67:5434-5442.
142. Godbey W.T., Atala A. Directed apoptosis in Cox-2-overexpressing cancer cells through expression-targeted gene delivery. Gene Ther. 2003, 10:1519-1527.
143. Lanson N.A., Friedlander P.L., Schwarzenberger P., Kolls J.K., Wang G. Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis. Cancer Res. 2003, 63:7936-7941.
144. Irving J., Wang Z., Powell S., O'Sullivan C., Mok M., Murphy B., Cardoza L., Lebkowski J.S., Majumdar A.S. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ther. 2004, 11:174-185.
145. Fujiwara T., Kagawa S., Kishimoto H., Endo Y., Hioki M., Ikeda Y., Sakai R., Urata Y., Tanaka N., Fujiwara T. Enhanced antitumour efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy. Int. J. Cancer 2006, 119.
146. Huang P., Watanabe M., Kaku H., Kashiwakura Y., Chen J., Saika T., Nasu Y., Fujiwara T., Urata Y., Kumon H. Direct and distant antitumor effects of a telomeraseselective oncolytic adenoviral agent, OBP-301, in a mouse prostate cancer model. Cancer Gene Ther. 2008, 15:315-322.
147. Zhang Y., Qi J.C., Lian W.F., Cai W.Q., Li W., Liu K.L. The animal research of recombinant adenovirus controlled by human telomerase reverse transcriptase promoter in the treatment of human prostate cancer. Zhonghua Wai Ke Za Zhi 2006, 44:1252-1255.
148. Xing Y., Liu M., Du Y., Qu F., Li Y., Xiao Y., Zhao J., Zeng F., Xiao C. Tumor cellspecific blockade of CXCR4/SDF-1 interactions in prostate cancer cells by hTERT promoter induced CXCR4 knockdown: a possible metastasis preventing and minimizing Approach. Cancer Biol. Ther. 2008, 7.
149. Fullerton N.E., Boyd M., Mairs R.J., Keith W.N., Alderwish O., Brown M.M., Livingstone A., Kirk D. Combining a targeted radiotherapy and gene therapy approach for adenocarcinoma of prostate. Prostate Cancer Prostatic Dis. 2004, 7:355-363.
150. Song W., Dong Z., Jin T., Mantellini M.G., Nunez G., Nor J.E. Cancer gene therapy with iCaspase-9 transcriptionally targeted to tumor endothelial cells. Cancer Gene Ther. 2008, 15:667-675.
151. Cross D.S., Burmester J.K. Functional characterization of the GDEP promoter and three enhancer elements in retinoblastoma and prostate cell lines. Med. Oncol. 2008, 25:40-49.
152. Wang J., Zhang H., Liang R.X., Pang B., Shi Q.G., Huang P.T., Huang C.F., Zhou J.G. Identification and characterization of the novel human prostate cancer-specific PC-1 gene promoter. Biochem. Biophys. Res. Commun. 2007, 357:8-13.
153. Dzojic H., Cheng W.S., Essand M. Two-step amplification of the human PPT sequence provides specific gene expression in an immunocompetent murine prostate cancer model. Cancer Gene Ther. 2007, 14:233-240.
154. Lipinski K.S., Djeha H.A., Gawn J., Cliffe S., Maitland N.J., Palmer D.H., Mountain A., Irvine A.S., Wrighton C.J. Optimization of a synthetic beta-catenin-dependent promoter for tumor-specific cancer gene therapy. Mol. Ther. 2004, 10:150-161.
155. Gabril M.Y., Onita T., Ji P.G., Sakai H., Chan F.L., Koropatnick J., Chin J.L., Moussa M., Xuan J.W. Prostate targeting: PSP94 gene promoter/enhancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model. Gene Ther. 2002, 9:1589-1599.
156. Zhang J., Ramesh N., Chen Y., Li Y., Dilley J., Working P., Yu D.C. Identification of human uroplakin II promoter and its use in the construction of CG8840, a urotheliumspecific adenovirus variant that eliminates established bladder tumors in combination with docetaxel. Cancer Res. 2002, 62:3743-3750.
157. Xie X., Zhao X., Liu Y., Young C.Y., Tindall D.J., Slawin K.M., Spencer D.M. Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter. Hum. Gene Ther. 2001, 12:549-561.
158. Pramudji C., Shimura S., Ebara S., Yang G., Wang J., Ren C., Yuan Y., Tahir S.A., Timme T.L., Thompson T.C. In situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter. Clin. Cancer Res. 2001, 7:4272-4279.
159. Luo X.M., Liu J.Y., Su M.Q., Hao X.K. Detection of transcriptional activities of tumorspecific survivin promoter in human prostatic carcinoma. Zhonghua Nan Ke Xue 2007, 13:502-506.
160. Figueiredo M.L., Kao C., Wu L. Advances in preclinical investigation of prostate cancer GENE therapy. Mol. Ther. 2007, 15:1053-1064.
161. Uchida A., O'Keefe D.S., Bacich D.J., Molloy P.L., Heston W.D. In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy. Urology 2001, 58:132-139.
162. Liu T.C., Kirn D. Gene therapy progress and prospects cancer: oncolytic viruses. Gene Ther. 2008, 15:877-884.
163. Freytag S.O., Movsas B., Aref I., Stricker H., Peabody J., Pegg J., Zhang Y., Barton K.N., Brown S.L., Lu M., Savera A., Kim J.H. Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Mol. Ther. 2007, 15:1016-1023.
164. Advani S.J., Mezhir J.J., Roizman B., Weichselbaum R.R. ReVOLT: radiation-enhanced viral oncolytic therapy. Int. J. Radiat. Oncol. Biol. Phys. 2006, 66:637-646.
165. Yu D.C., Chen Y., Dilley J., Li Y., Embry M., Zhang H., Nguyen N., Amin P., Oh J., Henderson D.R. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res. 2001, 61:517-525.
166. Ryan P.C., Jakubczak J.L., Stewart D.A., Hawkins L.K., Cheng C., Clarke L.M., Ganesh S., Hay C., Huang Y., Kaloss M., Marinov A., Phipps S.S., Reddy P.S., Shirley P.S., Skripchenko Y., Xu L., Yang J., Forry-Schaudies S., Hallenbeck P.L. Antitumor efficacy and tumor-selective replication with a single intravenous injection of OAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer. Cancer Gene Ther. 2004, 11:555-569.
167. Freytag S.O., Stricker H., Peabody J., Pegg J., Paielli D., Movsas B., Barton K.N., Brown S.L., Lu M., Kim J.H. Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol. Ther. 2007, 15:636-642.